# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight and raises the price target...
West Pharmaceutical Servs's (NYSE: WST) short interest as a percent of float has risen 9.25% since its last report. Accordi...
Rothschild & Co analyst Jamie Clark initiates coverage on West Pharmaceutical Servs (NYSE:WST) with a Buy rating and ann...
Medpace, ICON, and West Pharma led last week's large-cap rally, driven by strong earnings beats and upgraded guidance.
UBS analyst John Sourbeer maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $285 to...
Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the ...